Shanghai Bao Pharmaceuticals Co., Ltd. (02659.HK)価格

Shanghai Bao Pharmaceuticals Co Ltd is a CN-based company operating in industry. The company is headquartered in Shanghai, Shanghai. The company went IPO on 2025-12-10. Shanghai Bao Pharmaceuticals Co Ltd is a China-based company principally engaged in research and development of pharmaceutical products. The firm leverages synthetic biology technology to develop and deliver recombinant biologic drugs, targeting conditions with limited treatment options and complex manufacturing challenges. The firm focuses on four areas, including large-volume subcutaneous drug delivery, antibody-mediated autoimmune conditions, drugs in assisted reproduction and recombinant biologic products as transformative alternative to traditional biochemical production. The Company’s Core Products comprise SJ02 (Slonva), a long-acting recombinant human follicle-stimulating hormone carboxyl-terminal peptide fusion protein (FSH-CTP), KJ017, a recombinant human hyaluronidase, and KJ103, an innovative recombinant immunoglobulin G (IgG)-degrading enzyme.